Cargando…
PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING
Autores principales: | Leslie, Lori, Tees, Michael, Flinn, Ian W., Rodriguez, Tulio, Baird, John H., Deol, Abhinav, Mead, Monica, Bachier, Carlos, Rapoport, Aaron P., Mcclune, Brian, Hoda, Daanish, Perales, Miguel-Angel, Zheng, Yan, Filosto, Simone, Davis1, Madison, Miao, Harry, Kim, Jenny J., Oluwole, Olalekan O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429396/ http://dx.doi.org/10.1097/01.HS9.0000976104.50042.ff |
Ejemplares similares
-
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2023) -
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
por: Neelapu, Sattva S., et al.
Publicado: (2022) -
P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Flinn, Ian W., et al.
Publicado: (2023) -
P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
por: Oluwole, Olalekan, et al.
Publicado: (2023) -
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
por: Perales, Miguel-Angel, et al.
Publicado: (2022)